Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26970589 | 0.86 | USP30 (0.34) | AAK1PRMT5WDR77LPAR1USP30 | |
| SCHEMBL31206495 | 0.76 | AAK1 (0.35) | AAK1PRMT5WDR77USP30 | |
| SCHEMBL29341854 | 0.76 | GSK3B (0.38) | AAK1PRMT5WDR77LPAR1USP30 | |
| SCHEMBL15591807 | 0.73 | PTGDR2 (0.36) | LPAR1PTGDR2MAPK14LCKCA1 | |
| SCHEMBL30863598 | 0.73 | MEN1 (0.46) | LPAR1PTGDR2MAPK14LCKCA1 | |
| SCHEMBL24049966 | 0.72 | AAK1 (0.36) | AAK1PRMT5WDR77USP30CA1 | |
| SCHEMBL20518894 | 0.72 | AAK1 (0.41) | AAK1PRMT5WDR77USP30BRD9 | |
| SCHEMBL111352 | 0.72 | USP30 (0.35) | AAK1PRMT5WDR77USP30 | |
| SCHEMBL32670723 | 0.72 | LCK (0.46) | USP30LCKCA1CA2 | |
| SCHEMBL22858337 | 0.71 | USP30 (0.33) | AAK1PRMT5WDR77USP30MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125389-A1 | MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125389-A1 | MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF | PKMYT1, PKN1, ROS1 | AAK1 2016/4885PRMT5 306/4885WDR77 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.